Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer With Germline BRCA1/2 Mutations

NCT05806515 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT05806515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05806515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer With Germline BRCA1/2 Mutations
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2024
Completion date
June 30, 2031
Enrollment
44 (estimated)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8